Investors cautioned to be wary of speculative stocks as 2025's biggest winners, like quantum and nuclear stocks, pull back due to profit-taking and stretched valuations.
Sanofi reports strong Q3 results, driven by record Dupixent sales and pipeline progress, despite vaccine headwinds.
P&G beats expectations, cuts tariff and commodity costs, and maintains full-year guidance despite challenging environment.
Investors cautioned to be wary of speculative stocks as 2025's biggest winners, like quantum and nuclear stocks, pull back due to profit-taking and stretched valuations.
Sanofi reports strong Q3 results, driven by record Dupixent sales and pipeline progress, despite vaccine headwinds.
P&G beats expectations, cuts tariff and commodity costs, and maintains full-year guidance despite challenging environment.